SMMT SUMMIT THERAPEUTICS ADR

Summit Announces Agreement For a Fundraising of approximately $50 Million

Summit Announces Agreement For a Fundraising of approximately $50 Million
EN
02/10/2020

Underlying

SMMTSUMMIT THERAPEUTICS ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SUMMIT THERAPEUTICS ADR

Free Trial
SMMT SUMMIT THERAPEU...

Summit Therapeutics Inc: 2 directors

Two Directors at Summit Therapeutics Inc bought 210,321 shares at between 3.726USD and 3.750USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...

SMMT SUMMIT THERAPEUTICS ADR
03/28/24 March 28, 2024 1 EN
 PRESS RELEASE
Free
SMMT SUMMIT THERAPEU...

Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Bill...

Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody $500 Million Upfront Payment to Activate the Partnership for Ivonescimab Menlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced a definitive agreement of its partnership with Akeso Inc. (HKEX Code: 9926.HK, “Akeso”), to in-license its breakthrough bispecific antibody, ivonescimab. Akeso is a pioneer and source originator in dev...

December 6, 2022 1 EN
 PRESS RELEASE
Free
SMMT SUMMIT THERAPEU...

Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandr...

Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. “Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs,” stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. “As we intend...

November 17, 2022 1 EN
 PRESS RELEASE
Free
SMMT SUMMIT THERAPEU...

Summit Therapeutics Inc. Reports Financial Results and Operational Pro...

Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022 Menlo Park, California, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter and nine months ended September 30, 2022. Financial Highlights Aggregate cash, accounts receivable, and tax credits receivable on September 30, 2022 totaled $138.4 million as compared to $89.0 million...

November 9, 2022 1 EN
 PRESS RELEASE
Free
SMMT SUMMIT THERAPEU...

Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sp...

Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022 Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole preserved the gut microbiome compared to vancomycin: both in composition and diversity of the microbiome community Ri-CoDIFy represents the largest and most comprehensive CDI assessment of the gut microbiome to date from over 600 CDI patients Ridinilazole’s features are consistent with the principles of good antibiotic stew...

October 20, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch